Skip to content

EORTC Quality of Life Measurement Strategies in Progressive Cancer

Measurement Strategies for Assessment of Health-related Quality of Life Outcomes in Cancer Patients With Progressive Disease

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06842654
Enrollment
20
Registered
2025-02-24
Start date
2025-06-02
Completion date
2026-01-19
Last updated
2026-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Brief summary

Rationale: Health-related quality of life (HRQOL) in people diagnosed with cancer is of increasing interest as an endpoint in clinical care and research. It helps keep track of patients' functioning and wellbeing, and informs the net clinical benefit of treatment. However, gathering HRQOL information becomes increasingly harder when patients experience disease progression. Therefore we need to develop measurement strategies of HRQOL within the progressive disease setting. Objective: The overall aim of the project is to develop recommendations to optimise the measurement and analysis of HRQOL outcomes of cancer patients within the progressive disease setting. The aim of this sub-study is to identify the preferences of patients, their carers as proxies, and health-care professionals (HCPs) about the research objectives, how often and how we should assess HRQOL, and how we might limit dropout over time. Sub-study design: An international, multi-centre study using semi-structured interviews. Procedures: Across Europe, we aim to interview adult people diagnosed with cancer who experience progressive disease (N=30), their carers as proxies (N=30), and HCPs involved in cancer care and/or research (N=15). The UK site will aim to recruit a maximum of 10 patients and 10 proxies. Patients and carers will be interviewed twice to evaluate whether preferences change over time. Study outcomes: Findings can help in optimising the measurement and analysis of HRQOL outcomes of cancer patients in the progressive disease setting. This will help to better inform both clinical decision-making and regulatory processes.

Interventions

None listed

Sponsors

University of Leeds
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

PATIENT- Adult (\> 18 years of age) * Histologically proven or radiologically diagnosed cancer * Clinical and/or radiological progressive disease according to RECIST criteria * Poor prognosis, i.e. expected survival time \<3 years according to the treating physician PROXIES - Adult (\> 18 years of age) * Partner, relative or close friend of a patient who is eligible according to the criteria specified above

Exclusion criteria

* Participants without understanding of the official language of the country in which they live * Participants with any psychiatric condition or cognitive impairment, as determined by the treating physician, that would hamper providing informed consent for research participation

Design outcomes

Primary

MeasureTime frameDescription
Optimise the measurement and analysis of HRQOL outcomes3 monthsInterview adult people diagnosed with cancer who experience progressive disease (N=10) and their carers as proxies (N=10). Patients and carers will be interviewed twice to evaluate if preferences change over time. This will develop recommendations to optimise the measurement and analysis of HRQOL outcomes of cancer patients within the progressive disease setting.

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 30, 2026